Cumberland Pharmaceuticals Inc (CPIX)
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company listed on the NASDAQ under the ticker CPIX. The company focuses on acquiring, developing, and commercializing prescription products for hospital acute care, gastroenterology, and oncology markets. Its portfolio includes Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Sancuso for chemotherapy-related nausea and vomiting, Vaprisol for certain hospitalized patients with hyponatremia, Vibativ for specific bacterial infections, and Tacilia for H. pylori infection. Cumberland also is advancing ifetroban, which has completed Phase II clinical trials across several potential indications, including conditions associated with Duchenne muscular dystrophy, liver and kidney disorders, and inflammatory or fibrotic diseases. The company has a strategic alliance with WinHealth Pharma Group Co. Limited and is headquartered in Nashville, Tennessee. Founded in 1999, Cumberland operates in the United States and selected international markets, including China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CPIX
|
$6.93
|
-5.3% Downside
|
Fair
|
Not available
|
Not available
|
Good
|
20.9%
|
November 10, 2026
|
6.2x
|
2.4x
|
109.7 M
|
108.2 M
|
4.2%
|
58.1%
|
1.2
|
-21.4%
|
